The promises of quantitative systems pharmacology modelling for drug development
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output. Prior to this, the cost of each NTE was considered to be rising exponentially, with compound failure occurring mainly in clinical phases. Quantitative systems pharmacology (QSP) modelling, as an additional tool in the drug discovery arsenal, aims to further reduce NTE costs and improve drug development success. Through in silico mathematical modelling, QSP can simulate drug activity as perturbations in biological systems and thus understand the fundamental interactions which drive disease pathology, compound pharmacology and patient response. Here we review QSP, pharmacometrics and systems biology models with respect to the diseases covered as well as their clinical relevance and applications. Overall, the majority of modelling focus was aligned with the priority of drug-discovery and clinical trials. However, a few clinically important disease categories, such as Immune System Diseases and Respiratory Tract Diseases , were poorly covered by computational models. This suggests a possible disconnect between clinical and modelling agendas. As a standard element of the drug discovery pipeline the uptake of QSP might help to increase the efficiency of drug development across all therapeutic indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., et al. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg015 · Cited by 3,060
COPASI—a COmplex PAthway SImulator
Hoops, S., Sahle, S., Gauges, R., Lee, C., Pahle, J., Simus, N., Singhal, M., Xu, L., Mendes, P., & Kummer, U. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl485 · Cited by 2,618
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918 · cited 1×
“At the turn of the 21st century, a prevalent view of the pharmaceutical industry productivity was that compound attrition throughout the drug discovery pipeline was increasing [1, 2] and that the annual output of new therapeutic entities (NTEs) was in decline [3].”
BackgroundSystems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., et al. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12049 · Cited by 373
BioModels: ten-year anniversary
Chelliah, V., Juty, N., Ajmera, I., Ali, R., Dumousseau, M., Glont, M., Hucka, M., Jalowicki, G., Keating, S., Knight-Schrijver, V., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1181 · Cited by 281
Self-citationModel-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Milligan, P. A., Brown, M. J., Marchant, B., Martin, S. W., van der Graaf, P. H., Benson, N., Nucci, G., Nichols, D. J., Boyd, R. A., Mandema, J. W., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.54 · Cited by 238
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
The impact of mathematical modeling on the understanding of diabetes and related complications
Ajmera, I., Swat, M., Laibe, C., Le Novère, N., & Chelliah, V (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.30 · Cited by 153 · cited 1×
“A concerted effort within the BioModels database has focused on models of diabetes [44].”
BackgroundSelf-citationSystems pharmacology for drug discovery and development: paradigm shift or flash in the pan?
Vicini, P., & van der Graaf, P. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.40 · Cited by 108
Peterson, M., & Riggs, M. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.20 · Cited by 77 · cited 1×
“In a follow-up review on the FDA’s application of the calcium homeostasis model [45, 46], Peterson and Riggs suggested that the QSP modelling field will be emboldened by milestone cases such as the Natpara® BLA in 2014 [39].”
MethodRecent developments in using mechanistic cardiac modelling for drug safety evaluation
Davies, M. R., Wang, K., Mirams, G. R., Caruso, A., Noble, D., Walz, A., Lavé, T., Schuler, F., Singer, T., & Polonchuk, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.003 · Cited by 66
Next-Generation Model-Based Drug Discovery and Development: Quantitative and Systems Pharmacology
Allerheiligen, S. R. B. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.81 · Cited by 56
Mishra, H., Polak, S., Jamei, M., & Rostami‐Hodjegan, A. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.26 · Cited by 24
Editorial: The emerging discipline of quantitative systems pharmacology
Leil, T. A., & Ermakov, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00129 · Cited by 21
Cited by
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02313-z · Cited by 77
The dawn of a new era: can machine learning and large language models reshape QSP modeling?
Androulakis, I. P., Cucurull-Sanchez, L., Kondic, A., Mehta, K., Pichardo, C., Pryor, M., & Renardy, M. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09984-5 · Cited by 22
Self-citationGoryanin, I., Goryanin, I., & Demin, O. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104448 · Cited by 21
Metadata
- Authors
- Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Le Novère, N.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2016
- Volume
- 14
- Pages
- 363-370
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2521450174
- Cited by
- 97
- References
- 23
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.